Saiid Zarrabian Healthcare News

Follow[dot]Health is a news alert service for Heathcare and Healthtech. We are following 40K entities across 30M news items - with 1M items added monthly. This is selected healthcare news for Saiid Zarrabian, which is filed under People. There are 81 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
10/11/2021 Kintara Therapeutics to Present at the LD Micro Main Event Conference
... this article SAN DIEGO , Oct. 11, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc . (Nasdaq: KTRA ), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announces today that its Chief Executive Officer, Saiid Zarrabian , will present a corporate overview at the 14 th Annual LD Micro Main Event Conference ...
PR Newswire
8/17/2021 Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma
... with potential to increase this total to 65 clinical trial centers worldwide. "The entire Kintara team remains enthused by the pace at which our treatment arm is being activated in the study," commented Saiid Zarrabian , Kintara's Chief Executive Officer. "With 26 sites already active, including the recent addition of prestigious ...
PR Newswire
8/12/2021 Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021
SAN DIEGO Kintara Therapeutics, Inc . (Nasdaq: KTRA ), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that its Chief Executive Officer, Saiid Zarrabian , will present at the Investor Summit Conference being held August 17 – 18, 2021. Mr ...
PR Newswire
8/4/2021 Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021 PR Newswire
5/4/2021 Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors PR Newswire
10/21/2020 Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083's Participation in the GBM AGILE Registrational Study PR Newswire
9/21/2020 Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates gurufocus.com
8/26/2020 Kintara Therapeutics (formerly DelMar Pharmaceuticals) to Present at the LD Micro 500 Virtual Conference on September 3rd, 2020 PR Newswire
8/26/2020 Kintara Therapeutics (formerly DelMar Pharmaceuticals) to Present at the LD Micro 500 Virtual Conference on September 3rd, 2020 BioSpace
8/20/2020 Kintara Therapeutics (Formerly DelMar Pharmaceuticals) Announces Completion of Merger with Adgero Biopharmaceuticals and Closing of $19.6 Million Private Placement Priced At-The-Market PR Newswire
7/17/2020 DelMar Pharmaceuticals to Host Conference Call to Discuss Proposed Acquisition of Adgero Pharmaceuticals PR Newswire
7/17/2020 DelMar Pharmaceuticals to Host Conference Call to Discuss Proposed Acquisition of Adgero Pharmaceuticals | Business & Finance | heraldchronicle.com PR Newswire
6/24/2020 DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083's Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research Benzinga
6/24/2020 DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083's Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research gurufocus.com
6/24/2020 DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research nfcr.org
6/24/2020 DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083's Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research PR Newswire
6/10/2020 DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline BioSpace
6/10/2020 DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline gurufocus.com
6/4/2020 Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme BioSpace
6/4/2020 Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme gurufocus.com
6/4/2020 Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals' VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme PR Newswire
5/13/2020 DelMar Pharmaceuticals Announces Fiscal Third Quarter 2020 Financial Results and Recent Corporate Updates PR Newswire
3/4/2020 DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors PR Newswire
3/4/2020 DelMar Pharmaceuticals [Nasdaq:DMPI] Reports Over 50% Enrollment in Phase 2 Clinical Trial of VAL-083 For Adjuvant Treatment of Brain Tumors Yahoo News
2/19/2020 DelMar Pharmaceuticals [Nasdaq:DMPI] Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 For First-Line Treatment of Brain Tumors PR Newswire